Related references
Note: Only part of the references are listed.Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model
Inhye E. Ahn et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases
Fortunato Morabito et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options
Jitka Malcikova et al.
BLOOD (2021)
Clinical Outcomes in Patients with Multi-Hit TP53 Chronic Lymphocytic Leukemia Treated with Ibrutinib
Christian Brieghel et al.
CLINICAL CANCER RESEARCH (2021)
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study
John C. Byrd et al.
CLINICAL CANCER RESEARCH (2020)
TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics
Elias Campo et al.
HAEMATOLOGICA (2018)